23.8.2007

Clinical Phase I study of new Flu Vaccine launched

Avir Green Hills Biotechnology (GHB) announced the start of the clinical phase I study for their novel influenza vaccine “Envax” which provides coverage against a wider range of influenza virus variants than is generally possible with conventional vaccines.

BIA Separations is a key member of the consortium that helped bring this innovative vaccine to this first step in the drug approval process.

Back